<DOC>
	<DOCNO>NCT01662895</DOCNO>
	<brief_summary>The main purpose study determine whether treatment deferoxamine mesylate sufficient promise improve outcome pursuing large clinical trial examine effectiveness treatment brain hemorrhage .</brief_summary>
	<brief_title>High-Dose Deferoxamine Intracerebral Hemorrhage</brief_title>
	<detailed_description>Several study show hemoglobin breakdown subsequent iron accumulation brain play role mediate secondary neuronal injury intracerebral hemorrhage ( ICH ) ; treatment iron chelator , deferoxamine ( DFO ) , provide neuroprotection animal model ICH . The investigator recently conclude phase-I , safety dose-finding study DFO patient ICH ; repeat daily intravenous ( IV ) infusion DFO dose 62 mg/kg/day ( maximum daily dose 6000 mg/day ) well-tolerated increase serious adverse event mortality . The current study build result assess potential utility DFO therapeutic intervention ICH . This prospective , multi-center , double-blind , randomize , placebo-armed , phase-II , futility clinical study determine maximum tolerate dose DFO sufficient promise improve outcome prior embark large-scale costly phase III study ass efficacy ICH . The investigator randomize 324 subject ICH equally ( 1:1 ) either DFO 62 mg/kg/day ( maximum daily dose 6000 mg/day ) , saline placebo , give continuous IV infusion 5 consecutive day . Treatment initiate within 24 hour ICH symptom onset . Subjects stratify base baseline ICH score ( 0-2 vs. 3-5 ) ICH onset-to-treatment time ( OTT ) window ( ≤12h vs. &gt; 12-24h ) , result randomization ratio 1:1 within ICH score OTT window stratum . The main objective : 1 . To assess whether would futile move DFO forward Phase III trial base end point good outcome ( define dichotomize modified Rankin Scale score 0-2 3 month ) . At conclusion study , proportion DFO-treated subject good outcome compare placebo proportion futility analysis . If DFO-treated proportion less 12 % great placebo proportion , would futile move DFO forward future Phase III test . 2 . To collect data treatment-related adverse event order ascertain patient ICH tolerate dose give extended 5-day duration infusion without experience unreasonable neurological complication , increase mortality , serious adverse event related DFO use . Secondary exploratory objective include : 1 . Determining overall distribution score mRS 3 month DFO-treated subject , perform dichotomize analysis consider proportion DFO- placebo-treated subject mRS 0-3 . 2 . Exploring difference early ( ≤12h ) late ( &gt; 12-24h ) OTT windows DFO treatment effect functional outcome . 3 . Obtaining data National Institute Health Stroke Scale ( NIHSS ) , Montreal Cognitive Assessment ( MoCA ) , Stroke Impact Scale-16 ( SIS-16 ) explore effect treatment neurological cognitive function . 4 . Examining effect DFO relative peri-hematoma edema ( PHE ) volume progression baseline post-treatment CT scan residual cavity volume/brain atrophy 90 day , compare placebo , potential marker DFO biological activity brain tissue . 5 . Exploring whether effect DFO outcome dependent initial ICH volume , adjust prognostic variable , determine specific limit ICH volume specify exclusion/inclusion criterion future study . 6 . Assessing incidence symptomatic cerebral edema ( unexplained increase NIHSS &gt; 4 point decrease GCS &gt; 2 point ) hospitalization , day 7 discharge whichever earlier . 7 . Exploring whether progression PHE radiological/biological marker activity correlate clinical outcome treatment effect DFO . Successful completion study provide crucial `` go/no-go '' signal DFO ICH . Futility discourage major phase III trial , whereas non-futility offer strong support phase III study detect clinical efficacy . Results study provide valuable information guide design sample size estimation potential future Phase III trial . ICH frequent cause disability death . A successful study demonstrate efficacy DFO would considerable public health significance . The HI-DEF study also provide opportunity `` bank '' blood sample participant future innovative research ICH . We , therefore , plan collect additional blood sample participant HI-DEF baseline , start study drug infusion , completion last infusion store analyzed future . The exact question ask test do future fully identify stage . If effort develop deferoxamine therapy ICH successful , future pharmacogenetic study may help define therapeutic target responder vs. non-responders deferoxamine therapy . We tentatively plan investigate relationship polymorphisms panel gene encode iron-handling protein ( include gene involve intra- extra-cellular iron metabolism , ceruloplasmin , haptoglobin , hemopexin , transferrin receptor , ferritin heavy- light-chain , heme-oxygenase 1 2 gene ) peri-hematoma edema ; outcome ; response deferoxamine therapy .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Cerebral Hemorrhage</mesh_term>
	<mesh_term>Deferoxamine</mesh_term>
	<criteria>1 . Age ≥ 18 ≤ 80 year 2 . The diagnosis ICH confirm brain CT scan 3 . NIHSS score ≥ 6 GCS &gt; 6 upon presentation 4 . The first dose study drug administer within 24h ICH symptom onset 5 . Functional independence prior ICH , define preICH mRS ≤ 1 6 . Signed date informed consent obtain . 1 . Previous chelation therapy know hypersensitivity DFO product 2 . Known severe iron deficiency anemia ( define hemoglobin concentration &lt; 7g/dL require blood transfusion ) 3 . Abnormal renal function , define serum creatinine &gt; 2 mg/dL 4 . Planned surgical evacuation ICH prior administration study drug ( placement catheter ventricular drainage contraindication enrollment ) 5 . Suspected secondary ICH relate tumour , rupture aneurysm arteriovenous malformation , hemorrhagic transformation ischemic infarct , venous sinus thrombosis 6 . Infratentorial hemorrhage 7 . Irreversibly impaired brainstem function ( bilateral fix dilate pupil extensor motor posturing ) 8 . Complete unconsciousness , define score 3 item 1a NIHSS ( Responds reflex motor autonomic effect totally unresponsive , flaccid ) 9 . Preexisting disability , define preICH mRS ≥ 2 10 . Coagulopathy define elevate aPTT INR &gt; 1.3 upon presentation ; concurrent use direct thrombin inhibitor ( dabigatran ) , direct factor Xa inhibitor ( rivaroxaban ) , lowmolecularweight heparin 11 . Taking iron supplement contain ≥ 325 mg ferrous iron , prochlorperazine 12 . Patients heart failure take &gt; 500 mg vitamin C daily 13 . Known severe hearing loss 14 . Known pregnancy , positive pregnancy test , breastfeed 15 . Patients know suspected able comply study protocol due alcoholism , drug dependency , noncompliance , live another state cause 16 . Positive drug screen cocaine upon presentation 17 . Any condition , judgement investigator , might increase risk patient 18 . Life expectancy le 90 day due comorbid condition 19 . Concurrent participation another research protocol investigation another experimental therapy 20 . Indication new DNR Comfort Measures Only ( CMO ) order implement within first 72 hour hospitalization .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Brain hemorrhage</keyword>
	<keyword>Cerebral Hemorrhage</keyword>
	<keyword>Deferoxamine</keyword>
	<keyword>Hi-DEF Trial</keyword>
</DOC>